logo
The Surprising Reason Costco Milk Stays Fresh Way Past Its Sell-By Date

The Surprising Reason Costco Milk Stays Fresh Way Past Its Sell-By Date

Yahoo22-07-2025
Want less grocery waste? You should be buying milk from Costco.
If you're buying milk at Costco, you've likely noticed that the price looks a little different from your usual grocery store.
Right now, a gallon of Kirkland Signature whole milk runs between $3.65 and $3.89, depending on the location of the bulk retailer. That's a decent difference from the national average of $4.03 per gallon, according to the June 2025 Consumer Price Index.
It's not the least expensive milk you can buy, but in a year when food prices for some staples have swung wildly, it's still one of the more stable grocery deals. And unlike many private-label staples, the lower price doesn't mean sacrificing quality. Instead, Costco's milk may actually undergo more testing and quality control than many name brands you're familiar with.
Under the FDA's Pasteurized Milk Ordinance, all Grade A milk sold in the United States must meet basic safety standards. This includes keeping somatic cell counts below 750,000 per milliliter, limiting total bacteria to fewer than 100,000 colonies, and chilling milk to below 45°F within two hours of milking. These rules are designed to prevent major lapses in food safety. Most dairies meet those marks through standard practices, and testing typically occurs once or twice a year, based on records and a few laboratory samples.
Related: Why This Might Be Everyone's Favorite Italian Ingredient at Costco
Costco, however, doesn't just settle for the required minimum. According to its 2023 Food Safety & Quality Audit Expectations, any supplier producing Kirkland-brand milk has to undergo surprise inspections at least once a year — or twice, if the facility is in China. These audits cover both the farm and the milk processing plant, and suppliers are expected to pass inspection with zero critical issues. If a facility scores below 85%, it faces re-auditing within 60 days. And if a supplier skips Costco's additional audit requirements, inspectors will return at the supplier's expense.
There's also a testing policy for every batch of milk that will bear the Kirkland name: 60 microbial tests are run before anything ships out. If even one of those fails, the product is held back.
Furthermore, water used during processing is monitored more closely than federal standards require. Public water systems are tested annually for E. coli, and private wells are checked each quarter. To keep its production precise, Costco rotates lead auditors every three years, bringing in new eyes to avoid complacency and make sure nothing slips through.
That extra scrutiny may help explain why so many Costco shoppers swear the store's milk lasts longer. On the r/Costco subreddit, dozens of members share their own experiences. One redditor says, '​​I find that with Costco milk it isn't even spoiled a week after the expiration date most times. Anyone else have this experience?' Another chimes in, saying, 'Yes. I prefer Costco milk because it does last longer than anything else.' It's not lab data, but it sounds like a pattern.
Related: The Internet Loves These 7 Premade Meals From Costco, and You Will Too
According to the Penn State Extension, milk from herds with lower somatic cell counts tends to stay fresher longer. If a dairy can keep its herd average below 200,000 cells per milliliter, that's considered top-tier quality. But if those numbers rise above 400,000, milk may spoil faster — and producers might even face penalties. The closer the milk is to that ideal range, the longer it tends to hold up once it lands in your fridge.
Cleaner milk from healthier herds, processed under stricter controls, generally lasts longer in real-world conditions, especially when it's left unused for several days. If you find that Kirkland milk routinely outlasts its printed date by two to three days, that's likely thanks to lower bacteria and cell counts verified by each lot's extensive testing. That eventually translates to fewer spoiled jugs, savings for your wallet, and less overall waste.
In a dairy industry built around scheduled inspections and spot checks, Costco's retailer-led model quietly raises the bar. Bulk pricing doesn't have to mean minimal oversight, and in this case, paying less might actually get you more.
Read the original article on Food & Wine
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care
Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care

Business Wire

time38 minutes ago

  • Business Wire

Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with non-metastatic prostate cancer. ArteraAI Prostate is now recognized as an FDA-regulated Software as a Medical Device (SaMD). The technology's De Novo authorization establishes a new product code category for future AI-powered digital pathology risk-stratification tools, and enables its implementation at the point of diagnosis at qualified pathology labs in the U.S. This capability addresses a critical gap in prostate cancer care by reducing delays in delivering actionable insights at diagnosis, helping clinicians and patients make informed treatment decisions with greater confidence. 'This is a defining moment for AI in cancer care,' said Andre Esteva, CEO and co-founder of Artera. 'The FDA's decision validates the power of our MMAI platform to deliver on our vision to create AI-guided tools that enable data-backed and tailored treatments for each patient, leading to more confidence throughout the cancer journey, and ultimately, save more lives.' 'This approval highlights the groundswell of excitement surrounding the incorporation of AI into clinical practice flows. We need to utilize deep learning AI models to augment and better refine what a pathologist is able to report and Artera is leading the charge,' said Dr. Adam Cole, Founder and CSO at TruCore Pathology Group. 'As the demand for pathology services continues to outpace available capacity, tools like ArteraAI Prostate are critical. Implementing this software enhances our ability to deliver personalized insights more quickly, improves workflow efficiency, and allows us to scale services while increasing the quality of care.' Earning FDA De Novo authorization is a rare achievement, designed for novel medical innovations. This accomplishment marks yet another milestone for Artera, spotlighting its leadership and unwavering commitment to scientific rigor and excellence. Notably, the FDA authorization includes a Predetermined Change Control Plan, granting Artera the ability to expand platform capabilities through validating compatibility with additional digital pathology scanners without requiring further 510(k) submissions. The De Novo authorization for ArteraAI Prostate follows its earlier Breakthrough Device Designation. While the De Novo authorization applies specifically to the ArteraAI Prostate medical device software, Artera's underlying MMAI platform is also commercially available through the ArteraAI Prostate Test, as a Laboratory Developed Test (LDT). With this milestone, Artera continues to expand its pipeline of MMAI-powered software to support personalized cancer care. To learn more, visit About Artera Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera's MMAI platform leverages a patient's digitized biopsy images along with the patient's clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials, across different cancers, and is available in multiple versions across the globe. Artera's flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions. Additional MMAI-powered products include the ArteraAI Breast Test (UKCA), the ArteraAI Prostate Biopsy Assay (UKCA), and ArteraAI Prostate (FDA). Artera has regulatory authorization for its medical device product in the US and UK. Artera's headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit

Nationwide Coffee Recall as Products May Contain Glass
Nationwide Coffee Recall as Products May Contain Glass

Newsweek

time40 minutes ago

  • Newsweek

Nationwide Coffee Recall as Products May Contain Glass

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Dollar General Corporation has recalled select lots of its Clover Valley Instant Coffee products sold nationwide over concerns they may contain glass fragments. The recalled products were sold and distributed exclusively in Dollar General stores between July 9 and 21, the company said in an announcement published by the U.S. Food and Drug Administration (FDA). Newsweek contacted Dollar General Corporation for comment via email outside of regular office hours. Stock image. Dollar General Corporation has recalled select lots of its Clover Valley Instant Coffee products over concerns of glass contamination. Stock image. Dollar General Corporation has recalled select lots of its Clover Valley Instant Coffee products over concerns of glass contamination. Lino Mirgeler/picture-alliance/dpa/AP Why It Matters The FDA said that ingesting glass fragments "may cause injury to the consumer." "These injuries may include damage to teeth, laceration of the mouth and throat, or perforation of the intestine," it said. What To Know The recall applies to three lots of Dollar General's eight ounce Clover Valley Instant Coffee, with the UPC code: 876941004069. The affected lot numbers and best-by dates are the following: L-5163 - best-by: 12/13/2026 L-5164 - best-by: 12/13/2026 L-5165 - best-by: 12/14/2026 The recalled products were sold and distributed in every state other than Alaska and Hawaii, the FDA said. The recall was initiated after a customer notified Dollar General about the potential issue. As of August 12, no illnesses or injuries had been reported in connection with the products. The company said it was investigating the source of the glass contamination. It also encouraged customers who purchased the affected products to discard them and contact the company for a full refund. What People Are Saying Dollar General Corporation said in a recall announcement that it is "investigating the source of the glass contamination and apologizes for any inconvenience caused." Dr. Mark Fischer, regional medical director at International SOS, told Newsweek previously: "It can be dangerous to consume metals or other foreign objects found in food... [They] can cause cuts or internal injury and may need to be removed via a surgical procedure. If you swallow any foreign objects, it's best to consult a healthcare professional." What Happens Next Dollar General said it was investigating the source of the glass contamination. FDA inspectors are expected to carry out a hazard assessment before issuing one of three risk levels. The three classifications are:

Less-Than-Expected Inflation in July: Growth ETFs to Gain?
Less-Than-Expected Inflation in July: Growth ETFs to Gain?

Yahoo

timean hour ago

  • Yahoo

Less-Than-Expected Inflation in July: Growth ETFs to Gain?

The Consumer Price Index (CPI) increased 0.2% sequentially and 2.7% year over year, according to the Bureau of Labor Statistics (BLS). This compares with Dow Jones forecasts of 0.2% monthly and 2.8% annual growth, as quoted on CNBC. Core Inflation at Multi-Month Highs Excluding volatile food and energy prices, core CPI rose 0.3% in July and 3.1% annually, in line with monthly expectations but slightly above the 3% yearly forecast. The monthly core gain was the largest since January, while the annual pace was the highest since February. Federal Reserve officials typically view core inflation as a better indicator of long-term price trends. Market Reaction and Fed Rate Cut Speculation Following the CPI release, U.S. stock markets rallied, while Treasury yields were mixed. Investors boosted bets that the Federal Reserve could cut interest rates in September, with market pricing also indicating a possibility of another cut in rates in October. Fed officials are also concerned about labor market weakness, which could support the case for rate cuts. Analysts' Views Many economists believe tariff effects are likely to cause one-time price hikes rather than continued inflation, though the broad range of goods covered under Trump's tariffs has raised the chances of prolonged price pressures, as quoted on CNBC. Time for Growth Stocks? Growth stocks perform better in a low-rate environment. Low rates reduce the cost of borrowing, often needed to finance the expansion of companies. Lower rates reduce the attractiveness of fixed-income investments like bonds, leading investors to seek higher returns in the equity markets. Growth stocks, with their potential to offer high returns, become more appealing to investors in this environment, driving up their prices. ETFs to Buy Against this backdrop, below we highlight a few top-ranked growth-based exchange-traded funds (ETFs) that can be tapped if the Fed starts cutting rates soon. Vanguard Growth ETF VUG – Zacks Rank #1 (Strong Buy) Invesco S&P 500 Pure Growth ETF RPG – Zacks Rank #2 (Buy) Invesco Large Cap Growth ETF PWB – Zacks Rank #1 Vanguard S&P 500 Growth ETF VOOG – Zacks Rank #1 iShares S&P 500 Growth ETF IVW – Zacks Rank #1 Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Invesco S&P 500 Pure Growth ETF (RPG): ETF Research Reports Invesco Large Cap Growth ETF (PWB): ETF Research Reports Vanguard Growth ETF (VUG): ETF Research Reports iShares S&P 500 Growth ETF (IVW): ETF Research Reports Vanguard S&P 500 Growth ETF (VOOG): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store